NEFL and primary progressive multiple sclerosis: Used as the outcome measure in clinical trials with PPMS patients (INFORMS—fingolimod, ORATORIO—ocrelizumab), NfL level decreased during several months of treatment, parallel to clinical effects (slowed rate of disability accumulation) [72,73,74].